Details of the KEYNOTE-189 study have been announced by Merck (known as MSD outside the United States and Canada).
Browsing: Taxonomy > Immunotherapy
Keep checking back throughout the conference, we will be updating this article with the biggest news headlines from the American Association for Cancer Research (AACR) Annual Meeting 2018 (April 14–18, IL, USA).
Positive late-stage data has been announced from the KEYNOTE-054 trial, investigating KEYTRUDA® (pembrolizumab) in high-risk stage III melanoma patients.
What advancements have we witnessed in the field of immunotherapy for lung cancer and what does the future of this field look like? Find out in this article from Lung Cancer Management.
Discover details of the KEYNOTE-045, which recently resulted in the recommendation for the use of pembrolizumab within the cancer drugs fund as an option for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Pembrolizumab has become the first and only immunotherapy that NICE has recommended for urothelial carcinoma patients who have failed on platinum-containing chemotherapy.
Merck & Co. have signed a definitive agreement to acquire Viralytics for approximately $394 million, the companies has announced.
Discover details of Bristol-Myer Squibbs latest immuno-oncology drug deal, DiaCarta’s funding into its diagnostic platform and Cancer Research UK’s pledge to invest £45 million into clinical trials.
Delve deeper into the promising PD-L1 research being published, in this patient perspective piece from Stage IV melanoma patient T.J. Sharpe.